{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:38:07Z","timestamp":1789562287373,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T00:00:00Z","timestamp":1524787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T00:00:00Z","timestamp":1524787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pruritus is a common complication of cholestatic liver diseases. Inhibition of the ileal bile acid transporter (IBAT\/ASBT) may emerge as treatment option. Our aim was to assess tolerability and effect on pruritus of the selective IBAT inhibitor A4250 in patients with primary biliary cholangitis (PBC). Ten patients with PBC and bile acid sequestrant treatment of cholestatic pruritus were after a two-week wash out of the bile acid sequestrant treated with either 0.75\u2009mg (n\u2009=\u20094) or 1.5\u2009mg (n\u2009=\u20095) of A4250 for four weeks. Patients\u2019 pruritus was assessed by Visual Analogue Scale (VAS), 5-D itch scale and the pruritus module of the PBC40 questionnaire. Plasma bile acids and 7\u03b1-hydroxy-4-cholesten-3-one were measured by UPLC-MS\/MS, plasma fibroblast growth factor 19 by ELISA, and serum autotaxin activity by homemade assay. All nine patients exposed to A4250 reported a remarkable improvement in pruritus, until none or mild according to 5-D itch, VAS and PBC40 pruritus. Five patients finished the study prematurely due to abdominal pain (5\/5) and diarrhoea (4\/5). The high incidence of probably bile acid malabsorption-related diarrhoea and abdominal pain in the bile acid sequestrant pre-treated population indicates that the start dose of A4250 may have been too high for adult patients.<\/jats:p>","DOI":"10.1038\/s41598-018-25214-0","type":"journal-article","created":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T07:22:27Z","timestamp":1524468147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis"],"prefix":"10.1038","volume":"8","author":[{"given":"Samer","family":"Al-Dury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Wahlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staffan","family":"Wahlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Langedijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1779-0833","authenticated-orcid":false,"given":"Ronald Oude","family":"Elferink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"St\u00e5hlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7347-3085","authenticated-orcid":false,"given":"Hanns-Ulrich","family":"Marschall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,27]]},"reference":[{"key":"25214_CR1","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","volume":"386","author":"EJ Carey","year":"2015","unstructured":"Carey, E. J., Ali, A. H. & Lindor, K. D. Primary biliary cirrhosis. Lancet 386, 1565\u20131575, https:\/\/doi.org\/10.1016\/S0140-6736(15)00154-3 (2015).","journal-title":"Lancet"},{"key":"25214_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1542-3565(03)00134-4","volume":"1","author":"JA Talwalkar","year":"2003","unstructured":"Talwalkar, J. A., Souto, E., Jorgensen, R. A. & Lindor, K. D. Natural history of pruritus in primary biliary cirrhosis. Clin. Gastroenterol. Hepatol. 1, 297\u2013302 (2003).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"25214_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/hep.26909","volume":"60","author":"U Beuers","year":"2014","unstructured":"Beuers, U., Kremer, A. E., Bolier, R. & Elferink, R. P. Pruritus in cholestasis: facts and fiction. Hepatology 60, 399\u2013407, https:\/\/doi.org\/10.1002\/hep.26909 (2014).","journal-title":"Hepatology"},{"key":"25214_CR4","doi-asserted-by":"publisher","unstructured":"EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J. Hepatol., https:\/\/doi.org\/10.1016\/j.jhep.2017.03.022 (2017).","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"25214_CR5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens, F. et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N. Engl. J. Med. 375, 631\u2013643, https:\/\/doi.org\/10.1056\/NEJMoa1509840 (2016).","journal-title":"N. Engl. J. Med."},{"key":"25214_CR6","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/hep.23821","volume":"52","author":"EM Kuiper","year":"2010","unstructured":"Kuiper, E. M. et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology 52, 1334\u20131340, https:\/\/doi.org\/10.1002\/hep.23821 (2010).","journal-title":"Hepatology"},{"key":"25214_CR7","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/gut.50.3.436","volume":"50","author":"MI Prince","year":"2002","unstructured":"Prince, M. I., Burt, A. D. & Jones, D. E. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 50, 436\u2013439 (2002).","journal-title":"Gut"},{"key":"25214_CR8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/apt.13449","volume":"43","author":"VS Hegade","year":"2016","unstructured":"Hegade, V. S. et al. The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study. Aliment. Pharmacol. Ther. 43, 294\u2013302, https:\/\/doi.org\/10.1111\/apt.13449 (2016).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"25214_CR9","doi-asserted-by":"publisher","first-page":"744 e741","DOI":"10.1016\/j.amjmed.2017.01.037","volume":"130","author":"HD Trivedi","year":"2017","unstructured":"Trivedi, H. D., Lizaola, B., Tapper, E. B. & Bonder, A. Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review. Am. J. Med. 130, 744 e741\u2013744 e747, https:\/\/doi.org\/10.1016\/j.amjmed.2017.01.037 (2017).","journal-title":"Am. J. Med."},{"key":"25214_CR10","doi-asserted-by":"publisher","first-page":"33920","DOI":"10.1074\/jbc.M306370200","volume":"278","author":"PA Dawson","year":"2003","unstructured":"Dawson, P. A. et al. Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J. Biol. Chem. 278, 33920\u201333927, https:\/\/doi.org\/10.1074\/jbc.M306370200 (2003).","journal-title":"J. Biol. Chem."},{"key":"25214_CR11","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jhep.2015.10.024","volume":"64","author":"A Baghdasaryan","year":"2016","unstructured":"Baghdasaryan, A. et al. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. J. Hepatol. 64, 674\u2013681, https:\/\/doi.org\/10.1016\/j.jhep.2015.10.024 (2016).","journal-title":"J. Hepatol."},{"key":"25214_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/apt.13457","volume":"43","author":"H Graffner","year":"2016","unstructured":"Graffner, H., Gillberg, P. G., Rikner, L. & Marschall, H. U. The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation. Aliment. Pharmacol. Ther. 43, 303\u2013310, https:\/\/doi.org\/10.1111\/apt.13457 (2016).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"25214_CR13","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/ajg.2010.216","volume":"105","author":"T Kumagi","year":"2010","unstructured":"Kumagi, T. et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am. J. Gastroenterol. 105, 2186\u20132194, https:\/\/doi.org\/10.1038\/ajg.2010.216 (2010).","journal-title":"Am. J. Gastroenterol."},{"key":"25214_CR14","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/hep.25748","volume":"56","author":"AE Kremer","year":"2012","unstructured":"Kremer, A. E. et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology 56, 1391\u20131400, https:\/\/doi.org\/10.1002\/hep.25748 (2012).","journal-title":"Hepatology"},{"key":"25214_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1365-2036.2011.04675.x","volume":"34","author":"M Simren","year":"2011","unstructured":"Simren, M., Bajor, A., Gillberg, P. G., Rudling, M. & Abrahamsson, H. Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation\u2013a double-blind study. Aliment. Pharmacol. Ther. 34, 41\u201350, https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04675.x (2011).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"25214_CR16","doi-asserted-by":"publisher","unstructured":"Nakajima, A., Seki, M. & Taniguchi, S. Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial. J. Gastroenterol., https:\/\/doi.org\/10.1007\/s00535-017-1383-5 (2017).","DOI":"10.1007\/s00535-017-1383-5"},{"key":"25214_CR17","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","volume":"389","author":"VS Hegade","year":"2017","unstructured":"Hegade, V. S. et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet 389, 1114\u20131123, https:\/\/doi.org\/10.1016\/S0140-6736(17)30319-7 (2017).","journal-title":"Lancet"},{"key":"25214_CR18","first-page":"S1897","volume":"64","author":"MJ Mayo","year":"2016","unstructured":"Mayo, M. J. et al. CLARITY: a phase 2, randomized, double-blind, placebo controlled study of lopixibat chloride (formerly LUM001), a novel apical sodium-dependent bile acid transporter inhibitor, in the treatment of primary biliary cirrhosis associated with itching. J. Hepatol. 64, S1897 (2016).","journal-title":"J. Hepatol."},{"key":"25214_CR19","first-page":"646A","volume":"66","author":"E Sturm","year":"2017","unstructured":"Sturm, E. et al. The ileal bile acid transport inhibitor A4250 reduced pruritus and serum bile acid levels in children with cholestatic liver disease and pruritus: final results from a multiple-dose, open-label, multinational study. Hepatology 66, 646A (2017).","journal-title":"Hepatology"},{"key":"25214_CR20","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1136\/gut.2005.065862","volume":"54","author":"A Jacoby","year":"2005","unstructured":"Jacoby, A. et al. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut 54, 1622\u20131629, https:\/\/doi.org\/10.1136\/gut.2005.065862 (2005).","journal-title":"Gut"},{"key":"25214_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1365-2133.2009.09586.x","volume":"162","author":"S Elman","year":"2010","unstructured":"Elman, S., Hynan, L. S., Gabriel, V. & Mayo, M. J. The 5-D itch scale: a new measure of pruritus. Br. J. Dermatol. 162, 587\u2013593, https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09586.x (2010).","journal-title":"Br. J. Dermatol."},{"key":"25214_CR22","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3109\/00365529709011203","volume":"32","author":"SJ Lewis","year":"1997","unstructured":"Lewis, S. J. & Heaton, K. W. Stool form scale as a useful guide to intestinal transit time. Scand. J. Gastroenterol. 32, 920\u2013924, https:\/\/doi.org\/10.3109\/00365529709011203 (1997).","journal-title":"Scand. J. Gastroenterol."},{"key":"25214_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.cmet.2015.07.009","volume":"22","author":"V Tremaroli","year":"2015","unstructured":"Tremaroli, V. et al. Roux-en-Y Gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metab. 22, 228\u2013238, https:\/\/doi.org\/10.1016\/j.cmet.2015.07.009 (2015).","journal-title":"Cell Metab."},{"key":"25214_CR24","doi-asserted-by":"publisher","unstructured":"Kremer, A. E. et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 139, 1008\u20131018, 1018 e1001, https:\/\/doi.org\/10.1053\/j.gastro.2010.05.009 (2010).","DOI":"10.1053\/j.gastro.2010.05.009"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-25214-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-25214-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-25214-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T23:49:07Z","timestamp":1671580147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-25214-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,27]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["25214"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-25214-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,27]]},"assertion":[{"value":"21 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"6658"}}